ArticleFrontiers in neurology2019
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of CX-8998, a Selective Modulator of the T-Type Calcium Channel in Inadequately Treated Moderate to Severe Essential Tremor: T-CALM Study Design and Methodology for Efficacy Endpoint and Digital Biomarker Selection.
Article in Frontiers in neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- A Phase 2 Proof-of-Concept, Randomized, Placebo-Controlled Trial of CX-8998 in Essential Tremor.Movement disorders : official journal of the Movement Disorder Society · 2021Trial
- Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor.Tremor and other hyperkinetic movements (New York, N.Y.) · 2020Trial
- Treatment for essential tremor: a systematic review and Bayesian Model-based Network Meta-analysis of RCTs.EClinicalMedicine · 2024Article
- FAT1 weighted MRI: Diffusion meets anatomical imaging and application in thalamic surgery for tremor.Imaging neuroscience (Cambridge, Mass.) · 2024Article
- A mitochondrial inside-out iron-calcium signal reveals drug targets for Parkinson's disease.Cell reports · 2023Article
- T-type calcium channels as therapeutic targets in essential tremor and Parkinson's disease.Annals of clinical and translational neurology · 2023Review
- What's in a Name? Nomenclature of essential tremor: Syndrome or family of diseases?International review of neurobiology · 2022Article
- Essential tremor.Nature reviews. Disease primers · 2021Review
- Managing Essential Tremor.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
- Current and Future Neuropharmacological Options for the Treatment of Essential Tremor.Current neuropharmacology · 2020Review
- The Pharmacotherapeutic Landscape for Essential Tremor: Quantifying the Level of Unmet Need From a Patient and Epidemiologic Perspective.Clinical neuropharmacologyArticle
- Clinician- and Patient-reported Endpoints in CNS Orphan Drug Clinical Trials: ISCTM Position Paper on Best Practices for Endpoint Selection, Validation, Training, and Standardization.Innovations in clinical neuroscienceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.